Novonesis A/S/€NSISB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Novonesis A/S
Novonesis A/S is a biotechnology company formed in January 2024 through the merger of Novozymes and Chr. Hansen. Headquartered in Lyngby, Denmark, the company specializes in developing biosolutions, including enzymes, functional proteins, and microorganisms, serving over 30 industries such as food and beverage, agriculture, and pharmaceuticals. With a global presence encompassing more than 23 manufacturing sites and nearly 40 R&D and application centers, Novonesis employs approximately 10,000 individuals worldwide. The company is committed to sustainability, aiming for carbon neutrality by 2050 and a 75% reduction in scope 1 and 2 emissions by 2030. Novonesis leverages its extensive expertise to create innovative biosolutions that address global challenges in health, nutrition, and environmental sustainability.
Ticker
€NSISB
Sector
Primary listing
XGAT
Employees
10,582
Headquarters
Lyngby, Denmark
Website
Novonesis A/S Metrics
BasicAdvanced
€25B
27.47
€1.99
0.55
€0.86
1.58%
Price and volume
Market cap
€25B
Beta
0.55
52-week high
€65.61
52-week low
€49.31
Average daily volume
1.3K
Dividend rate
€0.86
Financial strength
Current ratio
1.752
Quick ratio
1.038
Long term debt to equity
27.69
Total debt to equity
30.92
Dividend payout ratio (TTM)
68.57%
Interest coverage (TTM)
15.48%
Profitability
EBITDA (TTM)
1,385.9
Gross margin (TTM)
57.72%
Net profit margin (TTM)
13.78%
Operating margin (TTM)
27.21%
Effective tax rate (TTM)
24.33%
Revenue per employee (TTM)
€390,000
Management effectiveness
Return on assets (TTM)
4.40%
Return on equity (TTM)
5.19%
Valuation
Price to earnings (TTM)
27.466
Price to revenue (TTM)
3.785
Price to book
17.7
Price to tangible book (TTM)
-409.64
Price to free cash flow (TTM)
27.268
Free cash flow yield (TTM)
3.67%
Free cash flow per share (TTM)
2.006
Dividend yield (TTM)
1.58%
Growth
Revenue change (TTM)
34.50%
Earnings per share change (TTM)
158.40%
3-year revenue growth (CAGR)
23.44%
10-year revenue growth (CAGR)
8.60%
3-year earnings per share growth (CAGR)
10.14%
10-year earnings per share growth (CAGR)
5.82%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
7.90%
Bulls say / Bears say
Robust bioenergy demand in India and Latin America helped offset negative currency effects, demonstrating diversified growth drivers (Reuters)
Management reiterated ambitious long-term targets of 6–9% compound annual revenue growth through 2030 and a 39% core profit margin, underlining confidence in strategic direction (Reuters)
Strategic exit from Russia earlier this year had only a modest impact on sales, reflecting disciplined portfolio optimization toward more scalable markets (Reuters)
Profit margins in Q2 fell short of market expectations as currency fluctuations and tariff-related costs eroded returns (Reuters)
The stock slid about 7% on weaker-than-expected Q2 results, highlighting investor sensitivity to near-term performance (Reuters) (Reuters)
Heavy reliance on bioenergy markets in emerging regions exposes the company to policy and pricing volatility, potentially impacting future revenue stability (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novonesis A/S stock?
Novonesis A/S (NSISB) has a market cap of €25B as of October 28, 2025.
What is the P/E ratio for Novonesis A/S stock?
The price to earnings (P/E) ratio for Novonesis A/S (NSISB) stock is 27.47 as of October 28, 2025.
Does Novonesis A/S stock pay dividends?
Yes, the Novonesis A/S (NSISB) stock pays dividends to shareholders. As of October 28, 2025, the dividend rate is €0.86398 and the yield is 1.58%. Novonesis A/S has a payout ratio of 68.57% on a trailing twelve-month basis.
When is the next Novonesis A/S dividend payment date?
The next Novonesis A/S (NSISB) dividend payment date is unconfirmed.
What is the beta indicator for Novonesis A/S?
Novonesis A/S (NSISB) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.